Obesity is not just a metabolic condition. It may also trigger frequent headaches and migraines.

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...

As CGRP-targeted therapies move into wider use, new data are beginning to clarify their role in special populations, the value of switching agents when one fails, and their long-term vascular safety.

Kallyope is a late-stage biotechnology company focused on developing innovative migraine and metabolic disease therapies for health challenges faced by hundreds of millions of people globally. Today ...

Slate Medicines, a new Raleigh biotechnology company developing treatments for migraine and headache disorders, has announced ...

An elevated serum calcitonin level is a highly sensitive marker for medullary thyroid carcinoma (MTC) that can be used for screening, differential diagnosis, prognostic assessment, follow-up ...

NICE has recommended new migraine pills, giving thousands faster relief from attacks and transforming treatment ...

Can the neurovascular effects of GLP-1s play a role in treating migraine?

The third phase of a migraine attack is the headache. This is when people typically experience a throbbing or pulsating ...

A key discovery in the field of headache research has been the association between migraine attacks and raised concentrations of calcitonin gene-related peptide (CGRP) in external jugular venous blood ...

For people with chronic migraine, taking glucagon-like peptide-1 receptor agonists, or GLP-1 drugs, for other conditions such ...

Chronic migraine sufferers taking GLP-1 drugs were about 10% less likely to need ER care for a migraine attack compared to those taking a standard first-line migraine drug, researchers are scheduled ...